RZG is presented as a viable alternative with stronger recent 1-year returns (34.14%) and higher concentration in healthcare, but comes with drawbacks including higher fees (0.35%), greater volatility (38.33% max drawdown), and narrower portfolio (126 holdings), making it suitable only for momentum-seeking investors comfortable with higher risk.
Delivered stronger 1-year returns (39.7%) but has higher expense ratio (0.35%), lower dividend yield (0.41%), smaller AUM ($143.1M), higher volatility (beta 1.12), and steeper 5-year drawdown (-38.30%). May outperform in growth-friendly markets but less suitable for long-term investors.
Articles that tag RZG but are mainly about other companies.
Articles and sentiment ratings from Massive / Polygon. Sentiment is the provider's model rating for this company, not Gainbot's view.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology